Research ArticleAccepted Article
Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study
Mark Genovese, Alberto Spindler, Akira Sagawa, Won Park, Anna Dudek, Alan Kivitz, Jeannie Chao, Lai Shan (Melanie) Chan, Jennifer Witcher, William Barchuk and Ajay Nirula
The Journal of Rheumatology December 2020, jrheum.200893; DOI: https://doi.org/10.3899/jrheum.200893
Mark Genovese
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Alberto Spindler
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Akira Sagawa
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Won Park
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Anna Dudek
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Alan Kivitz
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Jeannie Chao
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Lai Shan (Melanie) Chan
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Jennifer Witcher
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
William Barchuk
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Ajay Nirula
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Conflicts of Interest: M. C. Genovese is currently an employee of Gilead Sciences Inc. and holds stock options; he reports personal fees and other from Eli Lilly and Company, during the conduct of the study; personal fees and other from AbbVie, Gilead, and other from Galapagos, Pfizer, outside the submitted work; A Spindler has not conflicts to report; A Sagawa reports being a paid instructor for ONO Pharmaceutical, Eli Lilly Japan K.K., Takeda, AYUMI Pharmaceutical, Kissei Pharmaceutical, Chugai Pharmceutical, Asahi Kasei Pharma Corporation, and Janssen; W Park reports consulting fees from Celltrion; A Dudek has no conflicts to report; A Kivitz being a shareholder of Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, being paid consultant for AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., and on the speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie. J Chao, MLS Chan, J Witcher, and A Nirula are employees and stockholders of Eli Lilly; W Barchuk was an employee of Eli Lilly at the time of this study and currently is an employee of Gilead Sciences, Inc and owns Gilead stock. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study
Mark Genovese, Alberto Spindler, Akira Sagawa, Won Park, Anna Dudek, Alan Kivitz, Jeannie Chao, Lai Shan (Melanie) Chan, Jennifer Witcher, William Barchuk, Ajay Nirula
The Journal of Rheumatology Dec 2020, jrheum.200893; DOI: 10.3899/jrheum.200893
Accepted manuscript
Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study
Mark Genovese, Alberto Spindler, Akira Sagawa, Won Park, Anna Dudek, Alan Kivitz, Jeannie Chao, Lai Shan (Melanie) Chan, Jennifer Witcher, William Barchuk, Ajay Nirula
The Journal of Rheumatology Dec 2020, jrheum.200893; DOI: 10.3899/jrheum.200893